ADC Therapeutics SA
NYSE:ADCT
Balance Sheet
Balance Sheet Decomposition
ADC Therapeutics SA
Current Assets | 336.3m |
Cash & Short-Term Investments | 278.6m |
Receivables | 25.2m |
Other Current Assets | 32.5m |
Non-Current Assets | 18.5m |
Long-Term Investments | 1.6m |
PP&E | 16.1m |
Other Non-Current Assets | 711k |
Current Liabilities | 67.7m |
Accounts Payable | 15.6m |
Accrued Liabilities | 50.6m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 435.4m |
Long-Term Debt | 426.5m |
Other Non-Current Liabilities | 8.9m |
Balance Sheet
ADC Therapeutics SA
Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Cash & Cash Equivalents |
263
|
139
|
116
|
439
|
467
|
326
|
279
|
|
Cash Equivalents |
263
|
139
|
116
|
439
|
467
|
326
|
279
|
|
Total Receivables |
2
|
2
|
1
|
1
|
31
|
74
|
25
|
|
Accounts Receivables |
1
|
0
|
0
|
0
|
30
|
73
|
25
|
|
Other Receivables |
1
|
2
|
1
|
0
|
0
|
1
|
0
|
|
Inventory |
0
|
0
|
0
|
0
|
11
|
19
|
16
|
|
Other Current Assets |
1
|
2
|
6
|
10
|
17
|
27
|
16
|
|
Total Current Assets |
265
|
142
|
123
|
451
|
525
|
446
|
336
|
|
PP&E Net |
1
|
2
|
6
|
5
|
11
|
10
|
16
|
|
PP&E Gross |
1
|
2
|
6
|
5
|
11
|
10
|
0
|
|
Accumulated Depreciation |
1
|
1
|
3
|
4
|
4
|
3
|
0
|
|
Intangible Assets |
5
|
7
|
8
|
10
|
14
|
14
|
0
|
|
Long-Term Investments |
0
|
0
|
0
|
48
|
41
|
31
|
2
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
27
|
28
|
1
|
|
Total Assets |
272
N/A
|
151
-45%
|
138
-9%
|
514
+273%
|
618
+20%
|
529
-14%
|
355
-33%
|
|
Liabilities | ||||||||
Accounts Payable |
8
|
7
|
3
|
5
|
12
|
12
|
16
|
|
Accrued Liabilities |
4
|
5
|
6
|
12
|
16
|
16
|
51
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
1
|
5
|
8
|
14
|
1
|
|
Other Current Liabilities |
9
|
11
|
10
|
19
|
38
|
57
|
0
|
|
Total Current Liabilities |
21
|
22
|
20
|
40
|
74
|
99
|
68
|
|
Long-Term Debt |
0
|
0
|
4
|
37
|
313
|
316
|
426
|
|
Other Liabilities |
2
|
2
|
3
|
101
|
65
|
25
|
9
|
|
Total Liabilities |
23
N/A
|
24
+7%
|
27
+9%
|
178
+572%
|
452
+154%
|
440
-3%
|
503
+14%
|
|
Equity | ||||||||
Common Stock |
0
|
0
|
4
|
6
|
6
|
7
|
0
|
|
Retained Earnings |
204
|
326
|
443
|
652
|
822
|
925
|
0
|
|
Additional Paid In Capital |
452
|
452
|
550
|
981
|
982
|
1 008
|
0
|
|
Treasury Stock |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
148
|
|
Total Equity |
249
N/A
|
126
-49%
|
111
-12%
|
336
+202%
|
166
-50%
|
89
-47%
|
148
N/A
|
|
Total Liabilities & Equity |
272
N/A
|
151
-45%
|
138
-9%
|
514
+273%
|
618
+20%
|
529
-14%
|
355
-33%
|
|
Shares Outstanding | ||||||||
Common Shares Outstanding |
77
|
77
|
77
|
77
|
77
|
81
|
83
|